Roche (RHHVF) Stock Price, News & Analysis

Company Overview

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, Switzerland. The company operates through two core divisions—Pharmaceuticals and Diagnostics—focusing on the discovery, development and commercialization of innovative medicines and diagnostic tests. In its Pharmaceuticals segment, Roche is a global leader in oncology, immunology, infectious diseases and neuroscience, with a portfolio that includes targeted therapies such as monoclonal antibodies and small-molecule drugs designed to address unmet medical needs.

Founded in 1896 by Fritz Hoffmann-La Roche, the company has grown from a modest vitamin producer into one of the world’s largest biotech firms, with research and production sites spanning Europe, North America and Asia-Pacific. Under the leadership of CEO Thomas Schinecker, who took the helm at the start of 2023, Roche continues to pursue a strategy of personalized healthcare, leveraging advances in biomarkers and companion diagnostics to tailor treatments to individual patients.

Roche Diagnostics is recognized as a pioneer in in vitro diagnostics and tissue diagnostics, offering a broad range of instruments, reagents and software solutions. Its product suite includes molecular diagnostic platforms, immunoassays, clinical chemistry analyzers and point-of-care testing systems. These tools serve hospitals, clinical laboratories and research institutions worldwide, enabling healthcare providers to diagnose diseases earlier and monitor patient responses more effectively.

With a presence in over 100 countries, Roche emphasizes sustained investment in research and development, collaborating with academic institutions, biotech companies and healthcare organizations. The company’s integrated approach to pharmaceuticals and diagnostics underlines its commitment to advancing precision medicine and improving patient outcomes on a global scale.

Key Stats

• Today's Range: $319.60 to $325.85
• 50-Day Range: $304.39 to $335.49
• 52-Week Range: $269.80 to $354.19
• Volume: 893 shs
• Average Volume: 7,616 shs
• Market Capitalization: N/A
• P/E Ratio: 29.60
• Dividend Yield: 2.44%
• Price Target: N/A
• Consensus Rating: N/A

Roche Stock Analysis - MarketRank™

Roche scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Roche.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Roche is 30.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Roche is 30.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.08.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Roche has a short interest ratio ("days to cover") of 349.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Roche has recently decreased by 6.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Roche pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Roche does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Roche is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Roche has a short interest ratio ("days to cover") of 349.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Roche has recently decreased by 6.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Roche this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Roche insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 29.01% of the stock of Roche is held by institutions.

RHHVF Stock Analysis - Frequently Asked Questions

How have RHHVF shares performed this year?

Roche's stock was trading at $280.00 at the start of the year. Since then, RHHVF shares have increased by 16.3% and is now trading at $325.7020.

How do I buy shares of Roche?

Shares of RHHVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 7/24/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:RHHVF
• CIK: N/A
• Web: www.roche.com
• Phone: (161) 688-1111
• Fax: N/A
• Employees: 103,605
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 29.72
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A